Ductal Carcinoma In Situ: What the Pathologist Needs to Know and Why

Ductal carcinoma in situ is a proliferation of malignant epithelial cells confined to the ductolobular system of the breast. It is considered a pre-cursor lesion for invasive breast cancer and when identified patients are treated with some combination of surgery, +/− radiation therapy, and +/adjuvan...

Full description

Saved in:
Bibliographic Details
Main Author: Anita Bane
Format: Article
Language:English
Published: Wiley 2013-01-01
Series:International Journal of Breast Cancer
Online Access:http://dx.doi.org/10.1155/2013/914053
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832553010400591872
author Anita Bane
author_facet Anita Bane
author_sort Anita Bane
collection DOAJ
description Ductal carcinoma in situ is a proliferation of malignant epithelial cells confined to the ductolobular system of the breast. It is considered a pre-cursor lesion for invasive breast cancer and when identified patients are treated with some combination of surgery, +/− radiation therapy, and +/adjuvant tamoxifen. However, no good biomarkers exist that can predict with accuracy those cases of DCIS destined to progress to invasive disease or once treated those patients that are likely to suffer a recurrence; thus, in the era of screening mammography it seems likely that many patients with DCIS are overtreated. This paper details the parameters that should be included in a pathology report for a case of DClS with some explanations as to their importance for good clinical decision making.
format Article
id doaj-art-c4acc186827b4029a1183e70a16d038e
institution Kabale University
issn 2090-3170
2090-3189
language English
publishDate 2013-01-01
publisher Wiley
record_format Article
series International Journal of Breast Cancer
spelling doaj-art-c4acc186827b4029a1183e70a16d038e2025-02-03T05:57:12ZengWileyInternational Journal of Breast Cancer2090-31702090-31892013-01-01201310.1155/2013/914053914053Ductal Carcinoma In Situ: What the Pathologist Needs to Know and WhyAnita Bane0Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, L8V 1C3, CanadaDuctal carcinoma in situ is a proliferation of malignant epithelial cells confined to the ductolobular system of the breast. It is considered a pre-cursor lesion for invasive breast cancer and when identified patients are treated with some combination of surgery, +/− radiation therapy, and +/adjuvant tamoxifen. However, no good biomarkers exist that can predict with accuracy those cases of DCIS destined to progress to invasive disease or once treated those patients that are likely to suffer a recurrence; thus, in the era of screening mammography it seems likely that many patients with DCIS are overtreated. This paper details the parameters that should be included in a pathology report for a case of DClS with some explanations as to their importance for good clinical decision making.http://dx.doi.org/10.1155/2013/914053
spellingShingle Anita Bane
Ductal Carcinoma In Situ: What the Pathologist Needs to Know and Why
International Journal of Breast Cancer
title Ductal Carcinoma In Situ: What the Pathologist Needs to Know and Why
title_full Ductal Carcinoma In Situ: What the Pathologist Needs to Know and Why
title_fullStr Ductal Carcinoma In Situ: What the Pathologist Needs to Know and Why
title_full_unstemmed Ductal Carcinoma In Situ: What the Pathologist Needs to Know and Why
title_short Ductal Carcinoma In Situ: What the Pathologist Needs to Know and Why
title_sort ductal carcinoma in situ what the pathologist needs to know and why
url http://dx.doi.org/10.1155/2013/914053
work_keys_str_mv AT anitabane ductalcarcinomainsituwhatthepathologistneedstoknowandwhy